May 18, 2017. Patients with Duchenne muscular dystrophy and their loved ones deserve the benefits of the most rigorous research available. At the same time, investing in a clinical trial requires significant time and effort, and patients ALWAYS face risks without any guarantee of benefits. Patients and families who are willing to participate in a clinical trial that has the potential to benefit many should be fully informed about the potential risks and benefits of their participation in order to make a decision that is best for them.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony at the FDA about a Vaccine for Respiratory Syncytial Virus (RSV)
Megan Polanin May 17 2017: The NCHR advises the FDA to be cautious when approving RSV vaccines, emphasizing the need for strong evidence of safety and effectiveness, especially before giving them to infants who have never had RSV.
Read More »NCHR Comments to EPA on Use of Lead Free Pipes
May 17, 2017. We strongly support the EPA’s efforts to establish labeling requirements and assure compliance with lead free standards for plumbing products intended for potable water systems. These regulations will help professionals, including manufacturers, distributors, and retailers, to more easily identify lead free materials and prevent the use of those that are not. Ultimately, this will reduce consumers’ exposure to lead in drinking water and help to prevent its serious, detrimental, and often irreparable health effects.
Read More »NCHR Comments to EPA on Methylene Choloride and N-Methylpyrrolidone Use in Paint Remover
The NCHR asks the EPA to stop the use of methylene chloride and NMP in paint removers because they can cause serious health problems, including death. They believe that warning labels aren’t enough and that banning these chemicals is the best way to keep people safe.
Read More »NCHR Comments to FDA Advisory Committee on Organ Care System-Lung
The National Center for Health Research recommends the FDA postpone approval of the Organ Care System (OCS) Lung due to significant flaws in the INSPIRE trial, including design and implementation issues. These compromise the reliability of its findings and pose risks to patient safety.
Read More »